Monthly tralokinumab is an effective dosing regimen for patients with atopic dermatitis who have achieved stable disease control.
Community-acquired pneumonia (CAP) is a systemic disease and continues to be the leading cause of infectious mortality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback